ICAB PODS LIMITED

Financial Health Assessment: ICAB PODS LIMITED

1. Financial Health Score: F (Critical Condition)

Explanation: ICAB Pods Limited is in critical financial health. The business is technically insolvent, meaning its liabilities vastly exceed its assets, resulting in a negative net worth of over £580,000. The company's "financial pulse" (cash reserves) is dangerously faint at just £10,920, while it faces an overwhelming short-term debt burden that it currently cannot anatomically support. Without immediate intervention, the business is at severe risk of fatality (insolvency/administration).

2. Key Vital Signs

• Lung Capacity (Liquidity / Current Ratio): 0.17 – A healthy business typically has a current ratio of 1.5 or higher, meaning it has £1.50 of short-term assets for every £1 of short-term debt. ICAB Pods has only £0.17 of current assets (£347,898) to cover every £1 of current liabilities (£2,000,133). The patient is gasping for financial air.
• Blood Pressure (Cash Reserves): £10,920 – Cash has hemorrhaged from £88,224 in 2022 to just £10,920 in 2025. This represents a dangerously low cash pulse, leaving the business with almost no financial plasma to survive operational shocks.
• Body Mass Index (Solvency / Net Assets): -£580,052 – The company is financially emaciated. Total liabilities (£2,347,684 including provisions) drastically outweigh total assets (£347,898 + £1,439,734). The retained earnings (P&L reserve) show an accumulated loss of £580,452.
• Cholesterol Build-Up (Debt Structure): £1,764,462 – The most alarming vital sign is the "Insurance Claims Accommodation Bureau Loan Account" sitting in current liabilities at nearly £1.77 million. This single debt accounts for over 88% of the company's short-term obligations and is creating a massive blockage in the company's financial arteries.

3. Diagnosis

The patient is suffering from acute insolvency compounded by severe cash flow anemia.

While the business has a solid skeletal structure in the form of tangible fixed assets (£1,439,734 in pods, fixtures, and equipment), its working capital is hemorrhaging. The net current liabilities sit at a deficit of £1.65 million.

The primary pathology is the classification of the £1.77 million loan as a current liability (due within one year). If this loan is genuinely repayable on demand or within the next 12 months, the company does not have the liquidity to service it. However, if this is a related-party loan (which appears likely given the specific naming of the "Insurance Claims Accommodation Bureau"), the immediate risk of legal foreclosure may be mitigated, but the accounting reality remains: the business is technically balance-sheet insolvent.

Furthermore, the P&L reserve has deteriorated progressively over the last few years, moving from a positive position in 2022 to a deep deficit, indicating that the business model is currently burning through cash rather than generating it, despite increasing employee headcount from 18 to 20. There is also a notable provision of £367,551 on the balance sheet, which acts as a latent tumor representing future expected outflows, further draining financial health.

4. Recommendations

To stabilize the patient and prevent terminal decline, the following emergency interventions are required:

1. Emergency Tracheotomy (Debt Restructuring): The most critical action is to restructure the £1.77 million loan. If this is a related-party or long-term supportive loan, it must be formally reclassified as a long-term liability (due after more than one year) rather than a current one. This single accounting correction would immediately restore positive working capital and drastically improve the stated financial health, provided the lender agrees not to call it in within 12 months.
2. Blood Transfusion (Cash Flow Management): With only £10,920 in the bank, the business is operating on the edge of a cardiac arrest. Directors must halt non-essential cash outflows immediately. Additionally, the business is owed £336,978 by debtors; an aggressive collection strategy must be administered to transfuse vital cash into the business.
3. Review the Provisions (Biopsy): The £367,551 provision needs urgent review. Management must determine if this is an over-estimation that can be released back into the P&L, or if it represents a guaranteed future bleed that requires setting aside a formal payment plan.
4. Going Concern Viability Test: The directors must formally evaluate whether the company can continue as a going concern. They need written assurances from creditors (especially the loan holder) that they will not demand repayment within the next 12 months, allowing the business time to trade its way back to health.